Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally, and its
prevalence and impact are even more profound because sorafenib is the only systemic …

Hepatocellular carcinoma (HCC) is a major worldwide problem. Multiple chemotherapeutic
agents have been used both as single agents and in combination to treat advanced HCC …

Hepatocellular carcinoma (HCC) is the main cause of death in patients with cirrhosis, with
an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC. Over …

Hepatocellular carcinoma (HCC) is a major health problem. Most patients with HCC
experience a recurrence after resection/ablation or are diagnosed at advanced stages …

Purpose Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast
growth factor receptors that are implicated in the pathogenesis of hepatocellular carcinoma …

COmmEntaRY Gadaleta-Caldarola, Divella, Mazzocca et al. future science group
biomarkers and confirm that sorafenib may act by decreasing the RAS/RAF/MEK/ERK si …

Treatment of advanced-stage hepatocellular carcinoma (HCC) remains a challenge
because of the complex nature of the disease and the lack of available therapies. The …

Advanced hepatocellular carcinoma (aHCC) is a complex disease beset by underlying liver
dysfunction and high molecular heterogeneity. Sorafenib, introduced in 2007, is considered …

Sorafenib approval in patients with advanced hepatocellular carcinoma (HCC) was based
on two randomized, placebocontrolled, phase III trials. In those studies, sorafenib treatment …

Hepatocellular carcinoma (HCC) can be lethal due to its aggressive course and lack of
effective systemic therapies for advanced disease. Sorafenib is the only systemic therapy …